Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 82 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR European Parliament Adopts Its Position on the Critical Medicines Act, Strengthening Security of Cancer Care in Europe ESMO Raises Key Issues on Cancer Prevention and Care at the WHO Executive Board Meeting Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer MOST POPULAR Breast Cancer Patient Raising Money for 55 Women to Get Mammograms... December 4, 2020 What Survivors Should Know When Transitioning From Cancer Care to Primary... April 4, 2023 Coping With Social Isolation as a Teen With Cancer February 9, 2021 Molecular Analysis for Precision Oncology Congress 2024 London, UK, 16-18 October October 14, 2024 Load more HOT NEWS Jennifer Garner Shared A Video Of Her Mammogram Appointment Dunkin’ Customer Surprises Homeless Employee With Fully Furnished Home Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After... Sotorasib Shows Promising Activity and Acceptable Safety in Patients with Previously...
